{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:32:44Z","timestamp":1790775164146,"version":"4.1.0"},"reference-count":41,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40425-017-0258-x","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T10:29:01Z","timestamp":1498904941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment"],"prefix":"10.1136","volume":"5","author":[{"given":"Sooraj","family":"John","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Antonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor A.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Centeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben C.","family":"Creelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"258_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-014-0045-x","volume":"3","author":"N Rizvi","year":"2015","unstructured":"Rizvi N, Chaft J, Balmanoukian A, Goldberg SB, Sanborn RE, Steele KE, et al. Tumor response from durvalumab (MEDI4736)+ tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status. J Immunother Cancer. 2015;3:1.","journal-title":"J Immunother Cancer"},{"key":"258_CR2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","volume":"119","author":"JS Weber","year":"2013","unstructured":"Weber JS, Dummer R, de Pril V, Lebb\u00e9 C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab. Cancer. 2013;119:1675\u201382.","journal-title":"Cancer"},{"key":"258_CR3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1017\/S0317167100007939","volume":"36","author":"G Hunter","year":"2009","unstructured":"Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci. 2009;36:518\u201320.","journal-title":"Can J Neurol Sci"},{"key":"258_CR4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0046-8177(89)90128-7","volume":"20","author":"AM Emslie-Smith","year":"1989","unstructured":"Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989;20:224\u201331.","journal-title":"Hum Pathol"},{"key":"258_CR5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2249.1998.00664.x","volume":"113","author":"K Nagaraju","year":"1998","unstructured":"Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol. 1998;113:407\u201314.","journal-title":"Clin Exp Immunol"},{"key":"258_CR6","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1002\/art.27625","volume":"62","author":"T Sugihara","year":"2010","unstructured":"Sugihara T, Okiyama N, Suzuki M, Kohyama K, Matsumoto Y, Miyasaka N, et al. Definitive engagement of cytotoxic CD8 T cells in C protein\u2013induced myositis, a murine model of polymyositis. Arthritis Rheum. 2010;62:3088\u201392.","journal-title":"Arthritis Rheum"},{"key":"258_CR7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0022-510X(84)90086-8","volume":"65","author":"PC Blumbergs","year":"1984","unstructured":"Blumbergs PC, Byrne E, Kakulas BA. Polymyositis presenting with respiratory failure. J Neurol Sci. 1984;65:221\u20139.","journal-title":"J Neurol Sci"},{"key":"258_CR8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","volume":"17","author":"S Antonia","year":"2016","unstructured":"Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17:299\u2013308.","journal-title":"Lancet Oncol"},{"key":"258_CR9","first-page":"47","volume":"130","author":"JF Braidy","year":"1984","unstructured":"Braidy JF, Poulson JM. Diaphragmatic weakness and myositis associated with systemic juvenile rheumatoid arthritis. Can Med Assoc J. 1984;130:47\u20139.","journal-title":"Can Med Assoc J"},{"key":"258_CR10","doi-asserted-by":"crossref","first-page":"9661","DOI":"10.1016\/S0021-9258(18)98400-0","volume":"268","author":"CL Holness","year":"1993","unstructured":"Holness CL, da Silva RP, Fawcett J, Gordon S, Simmons DL. Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp\/lgp family. J Biol Chem. 1993;268:9661\u20136.","journal-title":"J Biol Chem"},{"key":"258_CR11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2990.2012.01302.x","volume":"38","author":"W Stenzel","year":"2012","unstructured":"Stenzel W, Goebel HH, Aronica E. Review: immune-mediated necrotizing myopathies--a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol. 2012;38:632\u201346.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"258_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002620100181","volume":"50","author":"TJ Paradis","year":"2001","unstructured":"Paradis TJ, Floyd E, Burkwit J, Cole SH, Brunson B, Elliott E, et al. The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma. Cancer Immunol Immunother. 2001;50:125\u201333.","journal-title":"Cancer Immunol Immunother"},{"key":"258_CR13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.24566","volume":"51","author":"AR Findlay","year":"2015","unstructured":"Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51:638\u201356.","journal-title":"Muscle Nerve"},{"key":"258_CR14","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.4049\/jimmunol.0803688","volume":"183","author":"AE Fasth","year":"2009","unstructured":"Fasth AE, Dastmalchi M, Rahbar A, Salomonsson S, Pandya JM, Lindroos E, et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol. 2009;183:4792\u20139.","journal-title":"J Immunol"},{"key":"258_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-016-0974-5","volume":"18","author":"JM Pandya","year":"2016","unstructured":"Pandya JM, Loell I, Hossain MS, Zong M, Alexanderson H, Raghavan S, et al. Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis. Arthritis Res Ther. 2016;18:1.","journal-title":"Arthritis Res Ther"},{"key":"258_CR16","doi-asserted-by":"crossref","first-page":"e36444","DOI":"10.1371\/journal.pone.0036444","volume":"7","author":"E Franck","year":"2012","unstructured":"Franck E, Bonneau C, Jean L, Henry J-P, Lacoume Y, Salvetti A, et al. Immunological tolerance to muscle autoantigens involves peripheral deletion of autoreactive CD8+ T cells. PLoS One. 2012;7:e36444.","journal-title":"PLoS One"},{"key":"258_CR17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4049\/jimmunol.169.1.515","volume":"169","author":"H Wiendl","year":"2002","unstructured":"Wiendl H, Malotka J, Holzwarth B, Weltzien H-U, Wekerle H, Hohlfeld R, et al. An autoreactive \u03b3\u03b4 TCR derived from a polymyositis lesion. J Immunol. 2002;169:515\u201321.","journal-title":"J Immunol"},{"key":"258_CR18","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1172\/JCI116533","volume":"91","author":"R Mantegazza","year":"1993","unstructured":"Mantegazza R, Andreetta F, Bernasconi P, Baggi F, Oksenberg J, Simoncini O, et al. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha\/beta rearrangements may indicate antigen-driven selection. J Clin Investig. 1993;91:2880.","journal-title":"J Clin Investig"},{"key":"258_CR19","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"T Kimura","year":"2016","unstructured":"Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107:1055\u20138.","journal-title":"Cancer Sci"},{"key":"258_CR20","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00520-014-2225-0","volume":"22","author":"S Koeppen","year":"2014","unstructured":"Koeppen S, Thirugnanasambanthan A, Koldehoff M. Neuromuscular complications after hematopoietic stem cell transplantation. Support Care Cancer. 2014;22:2337\u201341.","journal-title":"Support Care Cancer"},{"key":"258_CR21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00005792-199609000-00004","volume":"75","author":"P Parker","year":"1996","unstructured":"Parker P, Chao NJ, Ben-Ezra J, Slatkin N, Openshaw H, Niland JC, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine. 1996;75:279\u201385.","journal-title":"Medicine"},{"key":"258_CR22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10067-009-1350-5","volume":"29","author":"H Maillard-Lefebvre","year":"2010","unstructured":"Maillard-Lefebvre H, Morell-Dubois S, Lambert M, Charlanne H, Launay D, Hachulla E, et al. Graft-versus-host disease-related polymyositis. Clin Rheumatol. 2010;29:431\u20133.","journal-title":"Clin Rheumatol"},{"key":"258_CR23","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1096\/fj.03-0039fje","volume":"17","author":"H Wiendl","year":"2003","unstructured":"Wiendl H, Mitsdoerffer M, Schneider D, Chen L, Lochm\u00fcller H, Melms A, et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J. 2003;17:1892\u20134.","journal-title":"FASEB J"},{"key":"258_CR24","first-page":"154","volume":"41","author":"D Xiaoyu","year":"2011","unstructured":"Xiaoyu D, Yunxia W, Qi F, Dapeng W, Xiuying C, Jianhua J, et al. Expression of B7-homolog 1 in Polymyositis. Ann Clin Lab Sci. 2011;41:154\u201360.","journal-title":"Ann Clin Lab Sci"},{"key":"258_CR25","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.4049\/jimmunol.166.10.6430","volume":"166","author":"HB Wang","year":"2001","unstructured":"Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG. Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol. 2001;166:6430\u20136.","journal-title":"J Immunol"},{"key":"258_CR26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16:589\u201393.","journal-title":"Neuro-Oncology"},{"key":"258_CR27","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","volume":"33","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol. 2015;33:e122\u20134.","journal-title":"J Clin Oncol"},{"key":"258_CR28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone or in combination with ipilimumab in recurrent small-cell lung cancer. Lancet Oncol. 2016;17:883\u201395.","journal-title":"Lancet Oncol."},{"key":"258_CR29","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jtho.2016.11.011","volume":"12","author":"S Gadgeel","year":"2017","unstructured":"Gadgeel S, Ciardiello F, Rittmeyer A, Barlesi F, Cortinovis D, Barrios C, et al. PL04a. 02: OAK, a randomized ph III study of atezolizumab vs docetaxel in patients with advanced NSCLC: results from subgroup analyses. J Thorac Oncol. 2017;12:S9\u2013S10.","journal-title":"J Thorac Oncol"},{"key":"258_CR30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science. 2015;348:124\u20138.","journal-title":"Science"},{"key":"258_CR31","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/1538-7445.AM2013-1261","volume":"73","author":"J Quandt","year":"2013","unstructured":"Quandt J, Schlude C, Bartoschek M, Cid-Arregui A, Beckhove P, Momburg F. T cell responses against mutations in oncoproteins\/tumor suppressor proteins and their induction by vaccination with long peptides. Cancer Res. 2013;73:1261.","journal-title":"Cancer Res"},{"key":"258_CR32","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran E, Ahmadzadeh M, Lu Y-C, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350:1387\u201390.","journal-title":"Science"},{"key":"258_CR33","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375:2255\u201362.","journal-title":"N Engl J Med"},{"key":"258_CR34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","volume":"4","author":"QJ Wang","year":"2016","unstructured":"Wang QJ, Yu Z, Griffith K, Hanada K-I, Restifo NP, Yang JC. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol Res. 2016;4:204\u201314.","journal-title":"Cancer Immunol Res"},{"key":"258_CR35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","volume":"4","author":"MA Bilen","year":"2016","unstructured":"Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu S-M, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016;4:36.","journal-title":"J Immunother Cancer"},{"key":"258_CR36","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/1346-8138.12991","volume":"42","author":"M Yoshioka","year":"2015","unstructured":"Yoshioka M, Kambe N, Yamamoto Y, Suehiro K, Matsue H. Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol. 2015;42:1008\u20139.","journal-title":"J Dermatol"},{"key":"258_CR37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","volume":"38","author":"MM Chan","year":"2015","unstructured":"Chan MM, Kefford RF, Carlino M, Clements A, Manolios N. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015;38:37\u20139.","journal-title":"J Immunother"},{"key":"258_CR38","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210\u201325.","journal-title":"Eur J Cancer"},{"key":"258_CR39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","volume":"151","author":"SS Ali","year":"2015","unstructured":"Ali SS, Goddard AL, Luke JJ, Donahue H, Todd DJ, Werchniak A, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol. 2015;151:195\u20139.","journal-title":"JAMA Dermatol"},{"key":"258_CR40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","volume":"2","author":"L Min","year":"2014","unstructured":"Min L, Hodi FS. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res. 2014;2:15\u20138.","journal-title":"Cancer Immunol Res"},{"key":"258_CR41","first-page":"448","volume-title":"Annales de dermatologie et de venereologie","author":"M Lecouflet","year":"2012","unstructured":"Lecouflet M, Verschoore M, Giard C, Gohier P, Le Corre Y, Milea D, et al. Orbital myositis associated with ipilimumab. In: Annales de dermatologie et de venereologie; 2012. p. 448\u201351."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0258-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T08:52:27Z","timestamp":1659171147000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0258-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0258-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,18]]},"article-number":"54"}}